Andros Pharmaceuticals Co (ROCO:6917) Institutional Ownership: 0.00% (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6917 Andros Pharmaceuticals Co Ltd ROCO:6917
42 GF Score
Price NT$32.55
GF Value NT$285.87
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Andros Pharmaceuticals Co Institutional Ownership?

Andros Pharmaceuticals Co ROCO:6917 +0.46% 42 Institutional Ownership is 0.00% as of Aug. 23, 2026. GuruFocus rates ROCO:6917 with a GF Score™ of 42/100 and a GF Value™ of NT$285.87 (Possible Value Trap). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Andros Pharmaceuticals Co's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Andros Pharmaceuticals Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Andros Pharmaceuticals Co's Float Percentage Of Total Shares Outstanding is 0.00%.

Andros Pharmaceuticals Co Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Andros Pharmaceuticals Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Andros Pharmaceuticals Co Institutional Ownership Chart

Andros Pharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Institutional Ownership
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Andros Pharmaceuticals Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Institutional Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:6917
42GF Score
Andros Pharmaceuticals Co Ltd ROCO:6917
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Andros Pharmaceuticals Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.00% mean?
Andros Pharmaceuticals Co (ROCO:6917) has a Institutional Ownership of 0.00% as of Aug. 23, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Andros Pharmaceuticals Co and its competitors.
Is Andros Pharmaceuticals Co's Institutional Ownership too high?
Andros Pharmaceuticals Co's current Institutional Ownership is 0.00%. Overall, Andros Pharmaceuticals Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Andros Pharmaceuticals Co's Institutional Ownership compare to VRTX and REGN?
Andros Pharmaceuticals Co's Institutional Ownership of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Andros Pharmaceuticals Co and its competitors. Andros Pharmaceuticals Co's current Institutional Ownership is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Andros Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co (ROCO:6917) is currently considered Possible Value Trap. The stock's GF Value™ is NT$285.87, compared to a current price of NT$32.55 — trading 88.6% below its estimated fair value. The current Institutional Ownership is 0.00%. Andros Pharmaceuticals Co's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Andros Pharmaceuticals Co (ROCO:6917), the current Institutional Ownership is 0.00% as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?

Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$32.55 is trading 88.6% below its estimated GF Value™ of NT$285.87. GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.

Key valuation signals for ROCO:6917:

  • Institutional Ownership: 0.00%
  • GF Value™: NT$285.87 vs. price of NT$32.55 (88.6% below fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Andros Pharmaceuticals Co Business Description

Address No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
42GF Score

Get the complete analysis for ROCO:6917

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.55
Price
NT$285.87
GF Value